Continuous infusion of monoclonal antibody‐purified factor VIII
Continuous intravenous infusion of wet and dry heat treated factor VIII products has been shown to be an effective, safe, and convenient alternative to pulse‐dose therapy for the treatment of patients with hemophilia. We have used 12‐hr, single‐bottle continuous infusion of a factor VIII product pur...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 1991-03, Vol.36 (3), p.211-212 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 212 |
|---|---|
| container_issue | 3 |
| container_start_page | 211 |
| container_title | American journal of hematology |
| container_volume | 36 |
| creator | Weinstein, Ralph E. Bona, Robert D. Rickles, Frederick R. |
| description | Continuous intravenous infusion of wet and dry heat treated factor VIII products has been shown to be an effective, safe, and convenient alternative to pulse‐dose therapy for the treatment of patients with hemophilia.
We have used 12‐hr, single‐bottle continuous infusion of a factor VIII product purified from plasma sources by the use of monoclonal antibodies (Monoclate; Rorer Pharmaceutical Company) for the treatment of four bleeding episodes in three patients with severe hemophilia A. Patients required 2.1 U/kg/hr to attain an in vivo factor VIII level of 50 U/dl. Clinical hemostasis was achieved for all treatment episodes and no untoward effects of therapy were noted. Stability of the factor VIII:C levels in the product in vitro was also demonstrated.
We conclude from this preliminary data that continuous infusion of factor VIII products purified by monoclonal antibody technology is a safe, effective, and practical approach to the treatment of patients with hemophilia A. |
| doi_str_mv | 10.1002/ajh.2830360311 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80450912</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80450912</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3691-6d4a902b51ad46280191444f409a84b93efc28e077640d1b20dac404b3fc9d63</originalsourceid><addsrcrecordid>eNqFkLFOwzAQhi0EKqWwsiFlQGwpZ8cx9lhVQIMqsVSskePYwlVil7gR6sYj8Iw8CUapKBvTne7_7u7Xj9AlhikGILdy_TolPIOMQYbxERpjECzlLCfHaBynOPYgTtFZCGsAjCmHERphLoRgbIxmc--21vW-D4l1pg_Wu8SbpPXOq8Y72SQyApWvd18fn5u-s8bqOjFSbX2XvBRFcY5OjGyCvtjXCVo93K_mi3T5_FjMZ8tUZUzglNVUCiBVjmVNGeGABaaUGgpCclqJTBtFuIa7O0ahxhWBWioKtMqMEjXLJuhmOLvp_Fuvw7ZsbVC6aaTT0XzJgeYgMIngdABV50PotCk3nW1ltysxlD-RlTGy8hBZXLjaX-6rVtcHfMgo6td7XQYlG9NJp2z4xXIGhHIaMTFg77bRu3-elrOnxR8L3xvchE4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80450912</pqid></control><display><type>article</type><title>Continuous infusion of monoclonal antibody‐purified factor VIII</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Weinstein, Ralph E. ; Bona, Robert D. ; Rickles, Frederick R.</creator><creatorcontrib>Weinstein, Ralph E. ; Bona, Robert D. ; Rickles, Frederick R.</creatorcontrib><description>Continuous intravenous infusion of wet and dry heat treated factor VIII products has been shown to be an effective, safe, and convenient alternative to pulse‐dose therapy for the treatment of patients with hemophilia.
We have used 12‐hr, single‐bottle continuous infusion of a factor VIII product purified from plasma sources by the use of monoclonal antibodies (Monoclate; Rorer Pharmaceutical Company) for the treatment of four bleeding episodes in three patients with severe hemophilia A. Patients required 2.1 U/kg/hr to attain an in vivo factor VIII level of 50 U/dl. Clinical hemostasis was achieved for all treatment episodes and no untoward effects of therapy were noted. Stability of the factor VIII:C levels in the product in vitro was also demonstrated.
We conclude from this preliminary data that continuous infusion of factor VIII products purified by monoclonal antibody technology is a safe, effective, and practical approach to the treatment of patients with hemophilia A.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.2830360311</identifier><identifier>PMID: 1899966</identifier><identifier>CODEN: AJHEDD</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antibodies, Monoclonal - analysis ; Antibodies, Monoclonal - immunology ; Biological and medical sciences ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; continuous infusion ; Factor VIII - administration & dosage ; Factor VIII - immunology ; Factor VIII - isolation & purification ; Factor VIII - therapeutic use ; hemophilia ; Hemophilia A - drug therapy ; Humans ; Infusions, Intravenous ; Medical sciences ; monoclonal factor VIII ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>American journal of hematology, 1991-03, Vol.36 (3), p.211-212</ispartof><rights>Copyright © 1991 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3691-6d4a902b51ad46280191444f409a84b93efc28e077640d1b20dac404b3fc9d63</citedby><cites>FETCH-LOGICAL-c3691-6d4a902b51ad46280191444f409a84b93efc28e077640d1b20dac404b3fc9d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.2830360311$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.2830360311$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5602484$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1899966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weinstein, Ralph E.</creatorcontrib><creatorcontrib>Bona, Robert D.</creatorcontrib><creatorcontrib>Rickles, Frederick R.</creatorcontrib><title>Continuous infusion of monoclonal antibody‐purified factor VIII</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>Continuous intravenous infusion of wet and dry heat treated factor VIII products has been shown to be an effective, safe, and convenient alternative to pulse‐dose therapy for the treatment of patients with hemophilia.
We have used 12‐hr, single‐bottle continuous infusion of a factor VIII product purified from plasma sources by the use of monoclonal antibodies (Monoclate; Rorer Pharmaceutical Company) for the treatment of four bleeding episodes in three patients with severe hemophilia A. Patients required 2.1 U/kg/hr to attain an in vivo factor VIII level of 50 U/dl. Clinical hemostasis was achieved for all treatment episodes and no untoward effects of therapy were noted. Stability of the factor VIII:C levels in the product in vitro was also demonstrated.
We conclude from this preliminary data that continuous infusion of factor VIII products purified by monoclonal antibody technology is a safe, effective, and practical approach to the treatment of patients with hemophilia A.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antibodies, Monoclonal - analysis</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>continuous infusion</subject><subject>Factor VIII - administration & dosage</subject><subject>Factor VIII - immunology</subject><subject>Factor VIII - isolation & purification</subject><subject>Factor VIII - therapeutic use</subject><subject>hemophilia</subject><subject>Hemophilia A - drug therapy</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Medical sciences</subject><subject>monoclonal factor VIII</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLFOwzAQhi0EKqWwsiFlQGwpZ8cx9lhVQIMqsVSskePYwlVil7gR6sYj8Iw8CUapKBvTne7_7u7Xj9AlhikGILdy_TolPIOMQYbxERpjECzlLCfHaBynOPYgTtFZCGsAjCmHERphLoRgbIxmc--21vW-D4l1pg_Wu8SbpPXOq8Y72SQyApWvd18fn5u-s8bqOjFSbX2XvBRFcY5OjGyCvtjXCVo93K_mi3T5_FjMZ8tUZUzglNVUCiBVjmVNGeGABaaUGgpCclqJTBtFuIa7O0ahxhWBWioKtMqMEjXLJuhmOLvp_Fuvw7ZsbVC6aaTT0XzJgeYgMIngdABV50PotCk3nW1ltysxlD-RlTGy8hBZXLjaX-6rVtcHfMgo6td7XQYlG9NJp2z4xXIGhHIaMTFg77bRu3-elrOnxR8L3xvchE4</recordid><startdate>199103</startdate><enddate>199103</enddate><creator>Weinstein, Ralph E.</creator><creator>Bona, Robert D.</creator><creator>Rickles, Frederick R.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199103</creationdate><title>Continuous infusion of monoclonal antibody‐purified factor VIII</title><author>Weinstein, Ralph E. ; Bona, Robert D. ; Rickles, Frederick R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3691-6d4a902b51ad46280191444f409a84b93efc28e077640d1b20dac404b3fc9d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antibodies, Monoclonal - analysis</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>continuous infusion</topic><topic>Factor VIII - administration & dosage</topic><topic>Factor VIII - immunology</topic><topic>Factor VIII - isolation & purification</topic><topic>Factor VIII - therapeutic use</topic><topic>hemophilia</topic><topic>Hemophilia A - drug therapy</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Medical sciences</topic><topic>monoclonal factor VIII</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weinstein, Ralph E.</creatorcontrib><creatorcontrib>Bona, Robert D.</creatorcontrib><creatorcontrib>Rickles, Frederick R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weinstein, Ralph E.</au><au>Bona, Robert D.</au><au>Rickles, Frederick R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuous infusion of monoclonal antibody‐purified factor VIII</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>1991-03</date><risdate>1991</risdate><volume>36</volume><issue>3</issue><spage>211</spage><epage>212</epage><pages>211-212</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><coden>AJHEDD</coden><abstract>Continuous intravenous infusion of wet and dry heat treated factor VIII products has been shown to be an effective, safe, and convenient alternative to pulse‐dose therapy for the treatment of patients with hemophilia.
We have used 12‐hr, single‐bottle continuous infusion of a factor VIII product purified from plasma sources by the use of monoclonal antibodies (Monoclate; Rorer Pharmaceutical Company) for the treatment of four bleeding episodes in three patients with severe hemophilia A. Patients required 2.1 U/kg/hr to attain an in vivo factor VIII level of 50 U/dl. Clinical hemostasis was achieved for all treatment episodes and no untoward effects of therapy were noted. Stability of the factor VIII:C levels in the product in vitro was also demonstrated.
We conclude from this preliminary data that continuous infusion of factor VIII products purified by monoclonal antibody technology is a safe, effective, and practical approach to the treatment of patients with hemophilia A.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>1899966</pmid><doi>10.1002/ajh.2830360311</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 1991-03, Vol.36 (3), p.211-212 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80450912 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antibodies, Monoclonal - analysis Antibodies, Monoclonal - immunology Biological and medical sciences Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis continuous infusion Factor VIII - administration & dosage Factor VIII - immunology Factor VIII - isolation & purification Factor VIII - therapeutic use hemophilia Hemophilia A - drug therapy Humans Infusions, Intravenous Medical sciences monoclonal factor VIII Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | Continuous infusion of monoclonal antibody‐purified factor VIII |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T22%3A05%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuous%20infusion%20of%20monoclonal%20antibody%E2%80%90purified%20factor%20VIII&rft.jtitle=American%20journal%20of%20hematology&rft.au=Weinstein,%20Ralph%20E.&rft.date=1991-03&rft.volume=36&rft.issue=3&rft.spage=211&rft.epage=212&rft.pages=211-212&rft.issn=0361-8609&rft.eissn=1096-8652&rft.coden=AJHEDD&rft_id=info:doi/10.1002/ajh.2830360311&rft_dat=%3Cproquest_cross%3E80450912%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80450912&rft_id=info:pmid/1899966&rfr_iscdi=true |